European Drug Report 2024: Trends and Developments: source data
This data bundle contains all of the source data tables for the European Drug Report 2024: Trends and Developments. These data tables are used to generate the data visualisations and other tables in the report. Links to the source data tables to create data visualisations for specific sections can also be found at the bottom of each page, as well as, in most cases, beneath each graphic.
Notes:
- Note that the data set presented on this page is only a small subset of the data collected through our partner organisations. For more data and statistics, as well as for detailed methodological notes, caveats, please consult the Statistical Bulletin 2024, launched alongside this report.
- Unless otherwise stated, all data sets are fully compatible with the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. This means you are free to re-use our data and statistic in your work and research, provided you acknowledge us as the source.
- All files are in CSV (comma separated values) format which may be open by most spreadsheet or statistical software.
- Table EDR24-GPS-1. Prevalence of drug use in Europe, based on most recent general population surveys (2022 or most recent year)
- Table EDR24-GPS-2. Prevalence of drug use in Europe, trends
- Table EDR24-WW-1 Mean weekly measurements by targeted substance from wastewater analysis in selected European cities in 2023, in
- Table EDR24-TDI-1. Treatment demand indicator (TDI) source data, client characteristics, European Drug Report, 2024. Percentages except where otherwise stated
- Table EDR24-Stimulants-1. Amphetamine and methamphetamine entrants as a share of all first-time treatment entrants
- Table EDR24-Stimulants-2. Trends in all entrants for synthetic cathinone users
- Table EDR24- Stimulants-3. Synthetic stimulants seizures source data
- Table EDR24-Stimulants-4. Synthetic stimulants market price and purity data
- Table EDR24-Stimulants-5. Synthetic stimulants retail market price and purity data indexed trends (2012=100)
- Table EDR24-Stimulants-6. Trends in the number of synthetic stimulants seizures 2012-2022
- Table EDR24-Stimulants-7. Trends in the quantities of synthetic stimulants seized, tonnes 2012-2022
- Table EDR24-Sup-1. Number of reported drug seizures, breakdown by drug, 2022
- Table EDR24-Sup-2. Drug seizures in the European Union — number of drug seizures, indexed trends (2012 = 100)
- Table EDR24-Sup-3. Drug seizures in the European Union — quantity of drugs seized, indexed trends (2012 = 100)
- Table EDR24-Sup-4. Drug seizures in the European Union — number of seizures in 2022
- Table EDR24-Sup-5. Drug seizures in the European Union — quantity seized in 2022 (tonnes)
- Table EDR24-Sup-6. Drug law offences — possession/use offences, indexed trends (2012 = 100)
- Table EDR24-Sup-7. Drug law offences — supply offences, indexed trends (2012 = 100)
- Table EDR24-Sup-8. Drug law offences — number of offences, supply and use/possession, 2022
- Table EDR24-Sup-9. Summary of seizures of EU scheduled precursors and non-scheduled chemicals used for selected drugs produced in the European Union, 2021
- Table EDR24-BZD-1. Number of formal notifications of benzodiazepines reported to the EU Early Warning System, 2011-23
- Table EDR24-Ketamine-2. Ketamine residues detected in wastewater in selected European cities: most recent data
- Table EDR24-ketamine-1b. Seizures of ketamine powder in the European Union: total quantity, 2006-2022
- Table EDR24-Ketamine-1a. Seizures of ketamine powder in the European Union: total number, 2006–2022
- Table EDR24-OAT-1. Coverage of opioid agonist treatment in 2022 or the most recent year and 2011/12 (Percent)
- Table EDR24-OAT-2. Clients in opioid agonist treatment
- Table EDR24-OAT-3. Trends in the number in opioid agonist treatment
- Table EDR24-OAT-4. Number of European countries implementing opioid agonist treatment, up to 2023
- Table EDR24-NPS-1. Number of new psychoactive substances reported for the first time to the EU Early Warning System, by category, 2005–2023
- Table EDR24-NPS-2. Number of new psychoactive substances reported each year following their first detection in the European Union, by category, 2005–2022
- Table EDR24-NPS-3a. Seizures of new psychoactive substances in the European Union: total number and total quantity of material seized, 2005–2022
- Table EDR24-NPS-3b. Seizures of new psychoactive substances in the European Union: total number of material seized, 2005–2022
- Table EDR24-NPS-4. Number of opioids reported for the first time to the EU Early Warning System, 2009–2023
- Table EDR24-NPS-5. Seizures of new psychoactive substances in the European Union: quantity seized, by substance, 2022
- Table EDR24-NPS-6. Notifications of new psychoactive substances under the terms of Regulation (EC) no 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) – 2023
- Table 36 (edr2024-mdma-table-3.csv)
- Table EDR24-MDMA-2. MDMA markets seizures source data
- Table EDR24-MDMA-3. Trends in the number of MDMA seizures
- Table EDR24-MDMA-4. Trends in the quantity of MDMA seized: tablets
- Table EDR24-MDMA-5. Trends in the quantity of MDMA seized: powder (tonnes)
- Table EDR24-MDMA-6, price and purity or content data
- Table EDR24-MDMA-7. Price and MDMA content indexed trends
- Table EDR24-MDMA-8. MDMA purity or content of samples submitted to drug checking services (percent)
- Table EDR24-MDMA-9. Psychoactive adulterants detected in samples sold as MDMA to users and tested in 12 European drug checking s
- Table EDR24-INJ-1a. Estimated number and prevalence of people who inject drugs, by country (latest available data for each country)
- Table EDR24-INJ-1b. Estimated prevalence (per 1000 people) of people who inject drugs, (latest available data for each country)
- Table EDR24-INJ-2. Trends in injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine as primary drug: percentage reporting injecting as main route of administration
- Table EDR24-INJ-3a. European Syringe Collection and Analysis Project Enterprise (ESCAPE) selected data for 2022
- Table EDR24-INJ-3b. ESCAPE project site location data
- Table EDR24-DRID-1. New HIV notifications linked to injecting drug use in the European Union, 2009 to 2022
- Table EDR24-DRID-2. Most-recent HIV outbreaks in Europe among people who inject drugs and the associated injected substance, 2014 to 2022
- Table EDR24-DRID-3. Number of sterile syringes distributed per person who inject drugs per year, 2022 or latest data
- Table EDR24-DRID-4. Availability of needle syringe programmes in Europe at regional level, 2022 or the most recent year available
- Table EDR24-DRID-5a. New HIV cases attributable to injecting drug use
- Table EDR24-DRID-5b. New AIDS cases attributable to injecting drug use
- Table EDR24-DRID-5c. Trends in drug-related HIV: EU and selected countries (cases per million population)
- Table EDR24-DRID-5d. Countries with national data on HCV and HBV
- Table EDR24-DRID-6. Prevalence of active HCV infection among people who inject drugs, by country, 2022 or latest available data
- Table EDR24-Heroin-1. Age distribution of all clients entering treatment with heroin as their primary drug, 2010 and 2022 (%)
- Table EDR24-Heroin-2. Age distribution of never previously treated clients entering treatment with heroin as their primary drug, 2010 and 2022 (%)
- Table EDr24-Heroin-3. Trends in first-time heroin treatment entrants
- Table EDR24-Heroin-4. Trends in the main route of administration of clients entering treatment with heroin as primary drug, by treatment status (%)
- Table EDR24-Heroin-5. Heroin markets seizures source data
- Table EDR24-Heroin-6. Trends in the number of heroin seizures (x 1000)
- Table EDR24-Heroin-7. Trends in the quantities of heroin seizures (tonnes)
- Table EDR24-Heroin-8. Price, potency data for cannabis
- Table EDR24-Heroin-9. Price and purity/potency indexed trends
- Table EDR24-Heroin-10a. Proportion of the acute drug toxicity presentations with heroin involved in 2022
- Table EDR24-heroin-10b. Trends in the proportion of the acute drug toxicity presentations with heroin involved in selected hospitals in Europe
- Table EDR24-Heroin-11. Other opioids: number of seizures and quantities seized, 2022
- Table EDR24-HR-1. Number of European countries implementing harm reduction interventions, up to 2023
- Table EDR24-HR-2. Availability of take-home naloxone in Europe
- Table EDR24-HR-3. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2020 targets, 2022 or latest available estimate
- Table EDR24-HR-4. Location and number of drug consumption facilities throughout Europe 2023
- Table EDR24-HR-5. Availability of drug-related and other health and social care interventions targeting people who use drugs and are in prison, EU+2, 2022
- Table EDR24-DRD-1. Characteristics of drug-induced deaths
- Table EDR24-DRD-1a. Characteristics of drug-induced deaths: gender (percent)
- Table EDR24-DRD-1b. Characteristics of drug-induced deaths: age (by gender)
- Table EDR24-DRD-1c. Characteristics of drug-induced deaths: numbers
- Table EDR24-DRD-2. Age distribution of drug-induced deaths reported in the European Union, Norway and Türkiye in 2022 or the most recent year
- Table EDR24-DRD-3. Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2022, or most recent year (percent)
- Table EDR24-DRD-4. Drug-induced deaths in the European Union: age at death, 2022 or most recent available data (percent)
- Table EDR24-DRD-5. Number of drug-induced deaths reported in the European Union in 2012 and 2022, or the most recent year, by age band
- Table EDR24-DRD-6. Trends in drug-induced deaths in the European Union, Norway and Türkiye
- Table EDR24-DRD-7. Proportion of drug-induced deaths cases with opioids mentioned, 2022 or most recent available data
- Table EDR24-DRD-8. Proportion of drug-induced deaths with benzodiazepines involved, 2020 to 2022, selected countries among those with available information
- Table 87 (edr2024-cocaine-table-3.csv)
- Table EDR24-Cocaine-3. Trends in first-time entrants, cocaine, selected countries
- Table EDR24-Cocaine-4. Cocaine markets seizures source data
- Table EDR24-Cocaine-5. Trends in the number of cocaine seizures and quantity of illicit drugs seized (x 1000)
- Table EDR24-Cocaine-6. Trends in the quantities of cocaine seizures and quantity of illicit drugs seized (tonnes)
- Table EDR24-Cocaine-7. Price, potency data for cocaine
- Table EDR24-Cocaine-8. Price and purity/potency indexed trends
- Table EDR24-Cannabis-3. Trends in first-time entrants, cannabis, selected countries
- Table EDR24-Cannabis-4. Cannabis markets seizures source data
- Table EDR24-Cannabis-5. Trends in the number of cannabis seizures and quantity of illicit drugs seized (x 1000)
- Table EDR24-Cannabis-6. Trends in the quantities of cannabis seizures and quantity of illicit drugs seized (tonnes)
- Table EDR24-Cannabis-7. Price, potency data for cannabis
- Table EDR24-Cannabis-8. Price and purity/potency indexed trends
- Table EDR24-Annex-table-1a. High-risk opioid use estimates for population aged 15–64 years
- Table EDR24-Annex-table-1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands
- Table EDR24-Annex-table-1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration
- Table EDR24-Annex-table-1d. Number of clients in opioid agonist treatment
- Table EDR24-Annex-table-2a. Cocaine prevalence estimates among the general population and school students
- Table EDR24-Annex-table-2b. Entrants into treatment during the year - cocaine clients as a proportion of treatment demands
- Table EDR24-Annex-table-2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration
- Table EDR24-Annex-table-3a. Amphetamines prevalence estimates among the general population and school students
- Table EDR24-Annex-table-3b. Entrants into treatment during the year - amphetamines clients as a proportion of treatment demands
- Table EDR24-Annex-table-3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration
- Table EDR24-Annex-table-4a. MDMA prevalence estimates among the general population and school students
- Table EDR24-Annex-table-4b. Entrants into treatment during the year - MDMA clients as a proportion of treatment demands
- Table EDR24-Annex-table-5a. Cannabis prevalence estimates among the general population and school students
- Table EDR24-Annex-table-5b. Entrants into treatment during the year - cannabis clients as a proportion of treatment demands
- Table EDR24-Annex-table-6. Drug-induced deaths, HIV diagnoses, injecting drug use estimates, syringes distributed through specialised programmes
- Table EDR24-Annex-table-7. Seizures data
- (unused table)
- Table EDR24-Other-8. Number of seizures and quantity seized of other drugs